Nov 27 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental drug to treat severe major depressive disorder had failed to meet the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.07 USD | -2.48% | -0.78% | -17.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.35% | 287.31Cr | |
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals' depression drug fails to meet main goal in study